Human candidate polymorphisms in sympatric ethnic groups differing in malaria susceptibility in Mali. by Maiga, Bakary et al.
Maiga, B; Dolo, A; Tour, O; Dara, V; Tapily, A; Campino, S; Sepul-
veda, N; Risley, P; Silva, N; Corran, P; Rockett, KA; Kwiatkowski, D;
MalariaGEN Consortium; Clark, TG; Troye-Blomberg, M; Doumbo,
OK (2013) Human candidate polymorphisms in sympatric ethnic
groups differing in malaria susceptibility in mali. PLoS One, 8 (10).
e75675. ISSN 1932-6203 DOI: 10.1371/journal.pone.0075675
Downloaded from: http://researchonline.lshtm.ac.uk/1319745/
DOI: 10.1371/journal.pone.0075675
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Human Candidate Polymorphisms in Sympatric Ethnic
Groups Differing in Malaria Susceptibility in Mali
Bakary Maiga1,8*, Amagana Dolo1*¶, Ousmane Touré1, Victor Dara1, Amadou Tapily1, Susana Campino2,
Nuno Sepulveda3,4, Paul Risley5, Nipula Silva5, Patrick Corran3,5, Kirk A. Rockett2,6, Dominic
Kwiatkowski2,6, The MalariaGEN Consortium6, Taane G. Clark3,7¶, Marita Troye-Blomberg8¶, Ogobara K.
Doumbo1¶
1 Malaria Research and Training Center / Department of Epidemiology of Parasitic Diseases / Faculty of Medicine, Pharmacy and Odonto – Stomatology, BP
1805, Bamako, USTTB, Mali, 2 Wellcome Trust Sanger Institute, Hinxton, United Kingdom, 3 Faculty of Infectious and Tropical Diseases, London School of
Hygiene and Tropical Medicine, London, United Kingdom, 4 Center of Statistics and Applications of University of Lisbon, Lisbon, Portugal, 5 National Institute for
Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom, 6 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford,
United Kingdom, 7 Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom, 8 Department of
Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
Abstract
Malaria still remains a major public health problem in Mali, although disease susceptibility varies between ethnic
groups, particularly between the Fulani and Dogon. These two sympatric groups share similar socio-cultural factors
and malaria transmission rates, but Fulani individuals tend to show significantly higher spleen enlargement scores,
lower parasite prevalence, and seem less affected by the disease than their Dogon neighbours. We have used
genetic polymorphisms from malaria-associated genes to investigate associations with various malaria metrics
between the Fulanai and Dogon groups. Two cross sectional surveys (transmission season 2006, dry season 2007)
were performed. Healthy volunteers from the both ethnic groups (n=939) were recruited in a rural setting. In each
survey, clinical (spleen enlargement, axillary temperature, weight) and parasitological data (malaria parasite densities
and species) were collected, as well as blood samples. One hundred and sixty six SNPs were genotyped and 5
immunoassays (AMA1, CSP, MSP1, MSP2, total IgE) were performed on the DNA and serum samples respectively.
The data confirm the reduced malaria susceptibility in the Fulani, with a higher level of the protective O-blood group,
and increased circulating antibody levels to several malaria antigens (p<10-15). We identified SNP allele frequency
differences between the 2 ethnic groups in CD36, IL4, RTN3 and ADCY9. Moreover, polymorphisms in FCER1A,
RAD50, TNF, SLC22A4, and IL13 genes were correlated with antibody production (p-value<0.003). Further work is
required to understand the mechanisms underpinning these genetic factors.
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Introduction
Malaria remains the major public health problem in more
than 90 countries inhabited by more than 40% of the world’s
population, with at least one million deaths every year. More
than 90% of all malaria cases occur in sub-Sahara Africa [1]. In
Mali, there are over 800,000 recorded cases of malaria among
the 14 million people affected worldwide every year, and it
accounts for 17 percent of child deaths overall [2]. It is
therefore a major burden for the public health system, where
prevention, treatment and control measures are administered
by the Ministry of Health.
Malaria is a complex disease with many genetic and
environmental determinants influencing the natural variation in
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response to infection, progression and severity. Several factors
are important for the different phenotypes observed, such as
parasite genetic make-up, and host age, state of immunity and
host genetic background [3]. There are differences in malaria
infection and susceptibility between ethnic groups. In the
Gambia and Nigeria, studies have indicated that the Fulani
ethnic group has a higher frequency of splenomegaly than
other sympatric groups despite similar exposure [4,5]. In
Burkina Faso, a similar study showed that the Fulani have
lower parasite incidence, higher levels of humoral immune
responses to a variety of malaria parasite antigens than
Rimaibe and Mossi living in the same area [6,7]. There are also
inter-ethnic differences in susceptibility to malaria between the
two sympatric groups from Manterou in Mali, namely the Fulani
(also known as Peulh) and Dogon [8]. In particular, the Fulani,
tend to develop larger spleens, have lower parasite densities
and malaria prevalence than Dogon. The classical genetic
markers involved in malaria resistance, such as haemoglobin C
(HbC) and S (HbS) (in the HBB gene), glucose-6-phosphate
dehydrogenase (G6PD) and blood group polymorphisms [9],
are not sufficient to explain the differences between Fulani and
Dogon.
The main advantage of studying sympatric populations is
that geographical, environmental and epidemiological factors
are either the same or very similar between the groups, and
therefore it is believed that differences is the adaptation to the
environment may arise genetically [10]. Given the observations
from Burkina Faso and Mali of lower infection rates and higher
anti-malarial antibody levels in the Fulani compared to other
sympatric populations living in neighbouring villages [6,7,11],
one can hypothesize that there are genetic factors affecting the
underlying the humoral immune response to malaria. In Mali,
the Fulani ethnic group also shows a higher level of anti-
malaria humoral immune responses to a variety of Plasmodium
falciparum malaria antigens (CSP, AMA1, MSP1, MSP2) in a
context of similar malaria exposure [8]. Some of the genes
underlying these immune responses, particular those mediated
by inflammatory cytokines, have been associated with
susceptibility/resistance to severe malaria. These include
genes underlying cytokine production (e.g. TNF, LTA,
interleukins IL3, IL4, IL5, IL13, IL10, and interferon-γ)
(reviewed in 12). Other genes relevant to innate immunity have
also been reported, and include Toll-like receptors (TLR-2, 4,
and 9) [13]. The chromosomal region 5q31–33 contains many
of the genes above, as well as others related to cytokines,
growth factors and their receptors. By comparing the
polymorphisms in these genes, it will allow an assessment of
differences in allele frequency between the Fulani and other
sympatric populations.
In this study, we investigated a set of polymorphisms from
candidate genes linked to antibody production, malaria
susceptibility and resistance, in the Fulani and Dogon ethnic
groups in Mali, West Africa. This study consists of 939 subjects
genotyped at 166 single nucleotide polymorphisms (SNPs)
from genes involved in known malaria resistance (e.g. HBB,
G6PD), cytokine production (e.g. TNF, LTA, IL1, 3, 4, 5, 7, 10,
and 13), innate immunity (e.g. TLR 4,9) and the 5q31-33 region
(117 SNPs). The polymorphisms were correlated with antibody
levels to four P. falciparum antigens (CSP, AMA1, MSP1,
MSP2), which have been used as candidates in vaccines trials.
Ethnic differences in SNP allele frequencies and antibody
levels on clinical phenotypes, such as spleen enlargement,
parasitaemia and malaria outcome, are also assessed.
Materials and Methods
Study participants
The study was performed in a rural village of Manteourou,
875 km from Bamako, where people from the Dogon and
Fulani ethnic group live together in sympatry. This village lies
within the region known as the African Sahel. This region is
characterized by a dry season from October to May and a rainy
season from June to October [8]. The two groups live within
0.5km of each other where the Dogon (n=505, 53.8%) are
farmers who migrated from Bandiagara (110 km) to their
present location 50 years ago, while the nomadic Fulani
(Fulani, n=434, 46.2%) are cattle breeders who migrated 200
years ago from the area of Douentza situated 150 km from the
study area. Cultural and ethnic differences mean that there are
no inter-marriages between these two ethnic groups. According
to the general census before the study began, the population
size was estimated to be ~5000 inhabitants with 50% Dogon,
45% Fulani and 5% other ethnicities (Rimaibe, Mossi). The way
subjects are recruited is described in Diallo DA et al. 2005 [14].
Two cross sectional surveys were performed, the first at the
end of the transmission or rainy season (October/November
2006) and the second during the dry season (March/April
2007). The study included unrelated healthy volunteers,
children and adults, males and females, belonging to both
ethnic groups. At each survey, we have collected clinical
(spleen enlargement, axillary temperature, body weight) and
parasitological data (malaria parasite densities and species) as
well as blood samples.
Clinical information
Axillary temperature and spleen size were measured in all
participants. The spleen size was scored by Hackett’s method
and dichotomized as enlarged or not enlarged [15]. Thick blood
smears were collected and stained with 3% Giemsa and
examined for malaria parasites. Parasites and leukocytes were
counted. Parasite densities were estimated using an assumed
leukocyte count of 7500 leukocytes per microlitre of blood [8]. A
film was determined to be negative if no parasites were
identified in the course of examining sufficient fields for a total
of 300 leukocytes to be counted. Quality control through double
reading was also conducted on 10% of the slides randomly
selected by a separate physician. Parasitaemia was defined as
being present or absent. Clinical (mild) malaria was defined as
the presence of fever (axillary temperature of at least 37° 5C)
accompanied by detection of P. falciparum parasites on a thick
blood smear, in the absence of any other known illnesses.
Asymptomatic malaria was defined as the presence of P.
falciparum parasites, but no clinical symptoms. As this is a
cross-sectional survey there are no severe malaria cases of
malaria. Volunteers were followed-up for malaria incidence by
active and passive methods by the research team, which
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included a physician and biologist based in the health center of
the village of Manteourou.
Genotyping and immunoassays
All Genomic DNA samples (n=939) underwent whole
genome amplification through either Primer Extension Pre-
amplification (PEP) [16] before genotyping using the
Sequenom iPLEX MassArray platform [17,18]. One hundred
and sixty-six single nucleotide polymorphisms (SNPs),
predominantly located in genomic regions of malaria candidate
genes (e.g. sickle cell polymorphism HbS) were designed into
5 multiplexes. A full list of SNPs typed can be found in Tables
S1 and S2.
Serum was separated from the clotted blood samples by
centrifugation (12,000 rpm for eight minutes) and analysed by
ELISA for antibodies against four malarial antigens (AMA1,
MSP119, MSP2, CSP) and total IgE. Fifty microlitres of each
antigen at a dilution of 0.5 µg/mL (for AMA1 [3D7], MSP2 [3D7]
and IgE) or 1 µg/mL (for MSP1 [Wellcome genotype] and
NANP [NANP4]) were coated on ELISA plates (Immulon4
ELISA plates/Dynatech), and incubated at 4°C overnight.
Plates were washed 3 times with PBS-0.05% Tween 20
(PBS/T) before adding 200 µL of blocking solution (2%
skimmed milk in PBS/T) and then incubated for 3 hours at
ambient temperature before washing 3 times with PBS/T.
Serum samples were added in duplicate and incubated
overnight at 4°C. Following washing 6 times with PBS/T, 50 µL
of horseradish peroxidase-conjugated rabbit anti-human IgG
(DAKO) diluted 1/5,000 in PBS/T was added and incubated for
three hours at room temperature. The plates were again
washed 6 times with PBS/T and OPD substrate solution (100
μL/well) was added and left at room temperature for 10 to 15
minutes for the assay to develop. Twenty-five microlitres of
H2SO4 (2M) were added to stop the reaction and the plates
were read at 492 nm in an ELISA reader. The cut-off value of
the assay was determined by calculating the arithmetic mean
of the absorbance of negative control samples obtained from
European individuals who had never been exposed to malaria
and adding three standard deviations to that value (mean OD
+3SD). Using standard positive (Brefet4 pool [19], 0 and
negative controls (European pool), the positive-negative
threshold baseline was constructed using OD values obtained
upon ELISA and was used for calculation of the observed
antibody titres as described previously [20]. The titre values
were log10 transformed to symmetrise them for regression
analysis.
Ethical clearance
The study was given ethical clearance from the Institution
Committee on Ethics of the Mali School of Medicine Pharmacy
and Dentistry at the University of Bamako. Community
informed consent was obtained before the beginning of the
study. Individual oral consent was also obtained for each
examination or blood collection from adults or the parents or
guardians of children. The ethical clearance was obtained
through the Institutional Review Board of the Malian School of
Medicine Pharmacy and Dentistry at the University of Mali.
Treatment for malaria and other illnesses detected during the
course of the study was provided to the study population at no
cost to participants. Community permission was obtained
according to the procedures described by Diallo et al., in CID
2005 [14]. Individual written consent was then obtained for
each exam or blood collection from the adult or from the child’s
parent or care-givers.
Statistical analysis
All clinical and meta- data were double-entered from a case-
report form, and underwent range checks, where any outlier
was checked with written records and site staff. Mann-Whitney-
Wilcoxon sum-rank tests were used to assess overall ethnic
differences with continuous background (e.g. age in months)
and phenotypic (e.g. immunological titres) variables. Similarly,
Pearson’s χ2 independence tests were applied to categorical
variables (e.g. age group, parasite positivity). Genotypic
deviations from Hardy-Weinberg equilibrium (HWE) were
assessed using a χ2 statistical test. SNPs were excluded from
analysis if they had at least 10% of genotype calls missing or
there was significant deviation from HWE (p<0.0001). The SNP
association analysis for the (binary) malaria and clinical
phenotypes used a logistic regression model including age
group and season as covariates. The AMA1, MSP1, MSP2,
CSP assay results were logarithmically (base 10) transformed
in order to obtain Gaussian distributions approximately (see
Figure S1). The association analysis for continuous (log10
transformed) immunological titre phenotypes used linear
regression models, which included age group and season as
covariates. In all regression models, SNP data were included
by fitting a series of genetic models (additive, dominant,
recessive, heterozygous advantage, and general), and the
minimum p-value reported. Performing multiple statistical tests
leads to inflation in the occurrence of false positives. In our
setting a Bonferroni correction would be too conservative
because many of the SNPs are from a chromosome 5 region
and the same genes. We applied a permutation approach that
accounted for the correlation between tests, and estimated that
a p-value cut-off of 0.003 to ensure a global significance level
of 5%. All association analyses were performed on each ethnic
group separately. The Fst metric [21] was used to assess the
degree of genetic differentiation (0 = no differentiation, 1 =
complete differentiation) between the Fulani and Dogon ethnic
groups. All analyses were performed using the R statistical
software (http://www.r-project.org).
Results
The study enrolled 939 participants of which 53.8% were
Dogon and 46.2% are Fulani (Table 1). Data from each ethnic
group was reasonably matched for age, gender and seasonal
distribution (all p-values at least 0.05). However, there was a
significantly higher number of O blood individuals (known to be
protective against malaria [9]) in the Fulani (56.5%) compared
to Dogon (43.7%). Similarly, there was a higher frequency of
the HbC A allele in the Dogon (3.8%) compared to the Fulani
(0.6%) (P<0.001), and less clinical malaria cases in the Fulani
(6.9% vs. Dogon 12.5%, P=0.02). All immunoassays showed
greater median (geometric mean) levels in the Fulani (Table 1,
Human Genetic and Malaria Susceptibility in Mali
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Figure S2), with all being statistically significant (P<0.001) in
overall analysis, except total IgE (P=0.02). Multivariate analysis
of immunoassays adjusting for age and season, did not change
this result. Measures of infection rate, including
hyperparasitemia (p<0.005) and parasite density (P <0.005)
were significantly higher in Dogon compared to Fulani. Malaria
parasite positivity was marginally lower among the Fulani
(16.5%) than among the Dogon (21.6%). The proportion of
persons with enlarged spleen was significantly (P < 0.001)
higher in the Fulani (30.7%) than in the Dogon (8.8%) (see
Table 1). Similar results were obtained after adjusting for age,
gender and season (data not shown).
We compared the study characteristics between rainy and
dry seasons (Table S3). As expected, parasite positivity was
higher in the rainy season (30.6% versus 0.0%). There was
~70% reduced prevalence of spleen enlargement in the dry
season (odds ratio (OR) 0.305, 95% CI 0.209-0.447, P<10-5,
adjusting for ethnicity and age). CSP, AMA1 and IgE titres
show no differences between seasons, but MSP1 and MSP
were significantly lower during the dry season (P<10-5,
adjusting for ethnicity and age). There were modest
(Spearman) correlations between the AMA1, CSP, MSP1, and
MSP2 immunoassay measurements (median: 0.439, min.
0.266, max. 0.525), and less between these assays and total
IgE (median: 0.163, min. 0.148, max. 0.190) (Table S4). There
were low percentages of missing genotype data in each ethnic
group (median 5%). Using the 126 SNPs with low missing
genotype data and with minor allele frequency of at least 2%
Table 1. Study characteristics by ethnic group.
 Dogon (n=505, 53.8%)  Fulani (n= 434, 46.2%) P-value
 N (median) % (range)  N (median) %(Range)  
Age (in months) (204) (24-744)  (168) (24-900) 0.05
 0-4 years old 64 12.6  65 15.0 0.10
 5-9 years old 85 16.8  78 18.0  
 10-15 years old 86 17.0  93 21.4  
 >15 years old 270 53.5  198 45.6  
Male 219 43.4  192 44.2 0.84
Rainy season 332 65.7  262 60.4 0.10
AB0 blood group       
 0 195 43.5  237 56.5 <10-4
 A 90 20.1  87 20.8  
 B 136 30.4  78 18.6  
 AB 27 6.0  17 4.1  
Malaria       
 Clinical malaria 63 12.5  30 6.9  
 Asymptomatic 91 18.0  79 18.2  
 None 351 69.5  325 74.9 0.02
Immunological data       
 AMA1 (1078) (0 - 72,770)  (1742) (2-72,770) 10-3
 MSP1 (467) (0 - 131,800)  (2063) (19-356,900) <10-6
 MSP2 (1427) (0 - 777,500)  (3164) (49-777,500) <10-6
 CSP (679) (75-779,700)  (1338) (0 - 1,387,000) <10-6
 Total IgE (1403) (0 - 21,780)  (1662) (171-28,960) 0.02
Parasitological data       
 Parasite positivity 108 21.6  71 16.5 0.06
 Pf density (0) (0 - 3,034,000)  (0) (0 - 684,400) 0.02
 Hyperparasitaemia 56 11.1  25 5.8 <10-2
 Spleen enlargement 44 8.7  133 30.6 <10-6
Beta-globin HBB SNPs       
HbS        
  AA genotype 446 (96.3)  420 (97.9)  
  AS genotype 17 (3.7)  9 (2.1) 0.231
HbC        
  GG genotype 341 (92.4)  333 (99.1)  
  AG/AA genotypes 28 (7.6)  3 (0.9) <10-4
Hyperparasitaemia: parasitemia density greater than 10,000 parasites per microlitre; Parasite positivity: presence of one or more parasite per microlitre; Pf density:
number of parasite per microlitre; Spleen enlargement: presence of spleen enlargement; the P-values were calculated from a chi-squared test for qualitative variables and a
Mann-Whitney test for continuous variables.
doi: 10.1371/journal.pone.0075675.t001
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the degree of population differentiation between the ethnic
groups was small (Fst: median 0.013, range 0.000-0.428). The
rs3211938 polymorphism (CD36-aa325Y/stop [22]) had the
maximum Fst (G allele frequency: Dogon 0.680 vs. Fulani
0.047), with four others greater than 0.1 (rs2243250, IL4,
Fst=0.229; rs542998, RTN3, Fst=0.150; rs2243251, IL4,
Fst=0.140; rs10775349, ADCY9, Fst=0.105) (see Table S5 for
all results).
There were no strong effects of immunological variables on
clinical outcomes (P>0.03) (see Table S6, adjusted for age and
season) across each ethnic group. Increasing age was
associated with reduced risk of parasite positivity (P<10-5), but
not with spleen enlargement (P=0.133). We then considered
the role of the polymorphisms on malaria outcomes, spleen
enlargement and parasite positivity in each ethnic group
(adjusted for age and season) (see Figure 1, Table 2 for
significant results, Table S7 for all results). The rs3091336
(IL3) polymorphism was associated with asymptomatic and any
malaria in the Dogon (Asymptomatic OR 4.543, 95% CI
1.900-10.864, P=0.0007), whilst the rs2304081 (SLC22A4)
SNP was associated with these phenotypes in the Fulani ethnic
group (Any malaria OR 0.334, 95% CI 0.175-0.635, P=0.0004).
For clinical malaria, only significant associations were found in
the Fulani (rs17047661 (CR1), OR 5.327, 95% CI
1.733-16.376, P=0.0008; rs2075820 (NOD1), OR 0.364, 95%
CI 0.188-0.704, P=0.001). The rs1128127 polymorphism
(DERL3 gene) in the Dogon group was the only SNP
associated with spleen enlargement (OR 0.437; 95% CI
0.257-0.741, P=0.0014). Whilst there were five polymorphisms
associated with parasite positivity: (i) rs17047661 (CR1, Fulani
OR 2.874, 95% CI 1.505-5.487, P=0.0008); (ii) rs2304081
(SLC22A4, Fulani OR 0.277, 95% CI 0.120-0.639, P=0.0010);
(iii) rs3212227 (IL12B, Dogon OR 2.475, 95% CI 1.399-4.381,
P=0.0014); (iv) rs569108 (MS4A2, Dogon OR 0.466, 95% CI
0.288-0.755, P=0.0011); and (v) rs10775349 (ADCY9, Fulani
OR 2.471, 95% CI 1.355-4.506, P=0.0027). A combined
analysis (adjusting for ethnicity) identified no polymorphisms
associated with spleen enlargement, but one with parasite
positivity (rs3212227, IL12B, GT genotype vs. other OR 1.830,
95% CI 1.230-2.7219, P=0.0027. These effects did not change
markedly with adjustment for immunological assay data (results
not shown).
The effect of the candidate genetic polymorphisms on the
immunological assays was considered (adjusted for season
and age, Figure 2, Table 3 for significant results, Table S8
for all results). The associations detected (P<0.003) include:
(i) CSP (rs2251746, FCER1A gene, Dogon; rs3148, IL3,
Fulani; rs1800629 (TNF-308), Dogon; rs3093662, TNF,
Dogon), (ii) AMA1 (rs739718, IL5, Dogon), (iii) MSP1
(rs2304081, SLC22A4; rs2070722, IRF1; rs739718, IL5;
rs2239704, LTA; rs1799964, TNF; all Fulani hits), (iv) MSP2
(rs5743809, TLR6, Dogon; rs35415145, IL3, Fulani;
rs1799964, TNF, Fulani; rs1012356, IL22, Dogon), and (v) total
IgE (rs31481, IL3, Fulani; rs20541, IL13, Dogon; rs5498,
ICAM1, Fulani). A combined analysis (adjusted for age, season
and ethnicity) revealed the following polymorphisms: (i) CSP
(rs2251746, FCER1A, CC genotype vs CT/TT slope 1.466,
0.555-2.377, P= 0.0016; rs17772565, RAD50, CT vs. other
slope=-0.194, -0.320--0.067, P= 0.0026; rs1800629, TNF,
GG/GA vs. AA, 0.263, 0.094-0.432, P= 0.0023), (ii) MSP1
(rs2304081, SLC22A4, AA/AG vs. GG, 0.350, 0.154-0.546),
and (iii) total IgE (rs20541, IL13, TT vs. TC/CC, -0.209,
-0.346-0.072, P= 0.0028). There were no putative associations
for AMA1 and MSP2 in this combined analysis.
Discussion
This study considers two sympatric ethnic groups (Fulani and
Dogon) living in close proximity in Mali. Using standardized and
robust genetic and immunological assays, we found that the
Fulani ethnic group had significantly higher levels of total IgE
against crude malaria antigens relative to the Dogon ethnic
group. This confirms results from other studies in Burkina Faso
comparing the Fulani and Mossi ethnic groups (6,7]. In our
study, the Fulani had higher levels of spleen enlargement than
the Dogon, a result in line with previous findings in The Gambia
and Burkina Faso [4,6,7,11]. The higher total IgE and antigenic
(AMA1, CSP, MSP1 and MSP2) responses and the lower
parasite rate displayed among the Fulani ethnic group,
suggests a higher protection against P. falciparum in Fulani
compared with the Dogon, and potentially other sympatric
ethnic groups (consistent with [6,7]). This difference in
protection was observed despite the fact that the two ethnic
groups were apparently exposed to similar malaria
transmission dynamics. Both groups are known to have
different historic and geographic origins and other sociocultural
differences [8]. We identified that the Fulani tribe had a higher
prevalence of O blood group, which has an established
protective effect potentially through reduced P. falciparum
rosetting, which has been identified in other genetic studies in
Mali [9,23] and Kenya [23].
There was a difference in the genotypic profile at the HbC
polymorphism between the ethnic groups (AG/AA genotype:
Dogon 7.6%, Fulani 0.9%), in keeping with those reported in
Burkina Faso (6,7). We also found strong allele frequency
differences between ethnic groups in the rs3211938 (CD36,
under recent positive selection in Ghana [24]), rs2243250 and
rs2243251 (IL4, associated with malaria susceptibility [25],;
observed previously in the Gambia and other West African
populations [26]), rs542998 (RTN3) and rs10775349 (ADCY9)
(both identified in a recent Tanzanian case-control study [27]).
CD36 (Platelet glycoprotein IV) has been consistently found to
be a major ligand for adhesion of iRBC expressing PfEMP-1
[28,29], and it enhances phagocytosis and host clearance of
the parasite in the spleen, but its exact role in the pathogenesis
of malaria remains unresolved [30]. IL4 is an anti-inflammatory
cytokine involved in the regulation of the adaptive immunity
[31]. This cytokine is mainly produced by activated Th2 cells,
and induces proliferation and differentiation of activated B cells
and enhances the expression of MHC class II and the IgE low
affinity receptor (CD23) on resting B cells. In a study performed
in the same ethnic groups and region, the IL4-590 (T vs. C
alleles) was associated with higher parasite prevalence in
Fulani (compared to Dogon). Our data are also consistent with
the reported high correlation between the IL4 polymorphism
Human Genetic and Malaria Susceptibility in Mali
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and IgE production in asymptomatic individuals belonging to
the Fulani groups [32,33].
We identified genetic loci associated with CSP (FCER1A;
IL3; TNF), AMA1 (IL5), MSP1 (SLC22A4, IRF1, IL5, LTA,
TNF), MSP2 (TLR6, IL3, TNF, and IL22), and total IgE (IL3,
Figure 1.  The log10 p-values from applying SNP association tests for malaria and clinical phenotypes (from a logistic
regression adjusted for age and season).  (a) Clinical malaria.* dashed line represents a p-value of 0.003, polymorphisms are
ordered by chromosome (coloured differently) and position (see Tables S1 and S2).(b) Asymptomatic malaria.* dashed line
represents a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently) and position (see Tables S1 and
S2). (c) Any malaria. * dashed line represents a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently)
and position (see Tables S1 and S2). (d) Spleen enlargement. * dashed line represents a p-value of 0.003, polymorphisms are
ordered by chromosome (coloured differently) and position (see Tables S1 and S2). (a) Parasite positivity. * dashed line represents
a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently) and position (see Tables S1 and S2).
doi: 10.1371/journal.pone.0075675.g001
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IL13, and ICAM1). P. falciparum cytoadherence to ICAM-1 is
associated with cerebral malaria [34-36]. IL3 is a haematopetic
growth factor that stimulates survival, proliferation and
differentiation of haematopoetic cells, and results in a large
increase in both antigen and IgE-driven release of cytokines
and other mediators [37,38]. The rs40401-T variant occurs
significantly more frequently in Africans (particularly in malaria
endemic areas) than in Caucasians (HapMap version 3), and
combined with the known protection from immune disorders
provided by the alternate allele rs40401C in Caucasians,
suggest a selective pressure due to malaria [39]. Many
immunological studies have demonstrated the role of IL4, IL5
and IL13 in the immunomodulation and resistance to
schistosome infection in humans [40,41]. Furthermore, some
polymorphisms in the IL13 gene promoter region have been
shown to be associated with protection against severe malaria
in a Thailand study [42], and with S haematobium infections in
Mali [43]. Worm infections could have an involvement in the
malaria protection seen in the Fulani. In those patients with
non-malaria illness, the prevalence of worm infections is higher
in Fulani compared to the Dogon (Dolo A, 2005) [8]. In a study
from the same region in Mali, antibodies against S.
haematobium antigens have higher prevalence in Fulani
compared to Dogon (unpublished data). LTA and TNF have
long attracted attention as candidate genes for susceptibility
traits for malaria, and several of their polymorphisms have
been found to be associated with severe malaria phenotypes
[44]. It has been suggested that the causal polymorphisms
regulating TNF and LTA response may be some distance from
the genes, explaining the inconsistent association results in
these loci [45].
It is important to highlight some study limitations. First, it was
not possible to assess ethnic differences in seroprevalence
from the antibody titre data, as there was not a control
population for normalization [46]. Second, we measured total
IgE, but it may be more useful to derive parasite-specific
outcome in the future. Third, whilst our analyses included
information on age, ethnicity, antibody levels and genetic
variation, other informative data such as the use of routine
immunization against other diseases (e.g., tuberculosis),
duration and type of exposure were unavailable. Fourth, the
number of genetic polymorphisms considered (n=166) was
small in relation to a genome-wide association setting and
therefore other potential candidates could not be identified.
Fifth, no information about pregnant women susceptibility/
resistance to malaria and their offspring at the early stage of
life is available for either ethnic group. Finally, confirmation of
associations in independent cohorts is required, and follow-up
functional work would be needed to elucidate the underlying
mechanisms.
These potential limitations withstanding, our study confirms
and provides additional insights into the reduced malaria
susceptibility in the Fulani ethnic group. An unresolved issue is
whether pregnant Fulani women compared to Dogon are more
resistant to malaria. In general, further understanding of the
mechanisms underlying the reduced susceptibility of the Fulani
to malaria could provide essential information for the rational
design of malaria vaccines, monitoring of their trial, or
implementation of therapeutic strategies to improve public
health.
Table 2. Genetic association tests for malaria and clinical phenotypes by ethnic group.
    Alternative allele frequency, %   Genetic association analysis
 Alleles  Dogon  Fulani   Dogon   Fulani  
SNP (gene) Ref. Alt.  Control Case  Control Case  Comparison OR (95%CI) p-value  OR (95%CI) p-value
Clinical malaria                
rs17047661 (CR1) G A  23.6 27.6  35.6 51.7  AA/AG vs. GG 0.887 (0.453, 1.735) 0.706  5.327 (1.733, 16.376) 0.0008
rs2075820 (NOD1) A G  29.2 33.9  47.1 28.3  Additive G 1.232 (0.747, 2.031) 0.238  0.364 (0.188, 0.704) 0.001
Asymptomatic                
rs3091336 (IL3). G A  25.9 37.8  20.6 27.6  GG/AG vs. AA 4.543 (1.900, 10.864) 0.0007  1.553 (1.004, 2.400)* 0.049
rs2304081 (SLC22A4) G A  1.6 1.2  18.3 8.3  AA/GA vs. GG 0.782 (0.149, 4.100) 0.767  0.342 (0.167, 0.700) 0.002
Any malaria                
rs3091336 (IL3) G A  25.9 35.0  20.6 26.9  GG/AG vs. AA 3.692 (1.579, 8.634) 0.002  1.699 (1.026, 2.810)* 0.03
rs2304081 (SLC22A4) G A  1.6 2.0  18.3 7.9  AA/GA vs. GG 1.507 (0.446, 5.093) 0.51  0.334 (0.175, 0.635) 0.0004
Spleen enlargement                
 rs112812 (DERL3) A G  49.0 30.8  43.3 45.2  Additive G 0.437 (0.257,0.741) 0.0014  0.948 (0.683,1.316) 0.7496
Parasite positivity                
 rs17047661 (CR1) G A  24.1 28.8  35.8 45.8  GG/AG vs. AA 1.098 (0.637,1.893) 0.7371  2.874 (1.505,5.487) 0.0008
 rs2304081 (SLC22A4) G A  1.4 2.4  17.4 6.3  GG/AG vs. AA 2.360 (0.556,10.014) 0.2427  0.277 (0.120,0.639) 0.0010
 rs3212227 (IL12B) T G  34.4 40.2  29.8 30.3  GG/GT vs. TT 2.475 (1.399,4.381) 0.0014  1.260 (0.700,2.269) 0.4397
 rs569108 (MS4A2) A G  21.8 15.4  13.2 15.5  Additive G 0.466 (0.288,0.755) 0.0011  0.907 (0.515,1.600) 0.7364
 rs10775349 (ADCY9) C G  12.5 13.7  40.8 44.3  GC vs other 1.746 (0.893,3.416) 0.1043  2.471 (1.355,4.506) 0.0027
*. for a AA/GA vs. GG; Odds ratios (OR), 95% confidence intervals (CI) and p-values based on fitting logistic regression models adjusting for age group and season
doi: 10.1371/journal.pone.0075675.t002
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Conclusion
Our study showed that during the high and low transmission
seasons the Fulani tend to be less susceptible to P. falciparum
 malaria infection not only in parasite positivity but also in
parasite density than the Dogon. The results of our study
suggest that immunogenetic factors may be responsible for the
observed differences in malaria–related phenotypes between
Figure 2.  The log10 p-values from applying SNP association tests for immunological titre phenotypes (from a linear
regression adjusted for age and season).  (a) CSP. * dashed line represents a p-value of 0.003, polymorphisms are ordered by
chromosome (coloured differently) and position (see Tables S1 and S2). (b) AMA1. * dashed line represents a p-value of 0.003,
polymorphisms are ordered by chromosome (coloured differently) and position (see Tables S1 and S2). (c) MSP1. * dashed line
represents a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently) and position (see Tables S1 and
S2). (d) MSP2. * dashed line represents a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently) and
position (see Tables S1 and S2). (e) Total IgE. * dashed line represents a p-value of 0.003, polymorphisms are ordered by
chromosome (coloured differently) and position (see Tables S1 and S2).
doi: 10.1371/journal.pone.0075675.g002
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the Fulani and Dogon ethnic groups. These factors may be
helpful in understanding the precise mechanisms of resistance
in the nomadic Fulani population. This study was performed in
a rural setting and identifies some human genetic factors that
are involved in malaria susceptibility and resistance, and thus
strengthens previous observations.
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Table 3. Genetic association tests for (log10 transformed) immunoassay titre phenotypes by ethnic group.
    Alternative allele frequency (%)   Genetic association analysis
 Alleles     Dogon  Fulani
SNP, Gene Ref. Alt.  Dogon Fulani  Comparison Effect size (95% CI) p-value  Effect size (95% CI) p-value
CSP             
 rs2251746, FCER1A T C  4.9 13.1  CC vs TC/TT 2.601 (1.109,4.093) 0.0006  0.933 (-0.229,2.096) 0.1155
 rs3148, IL3 G A  8.8 6.4  AA vs AG/GG -0.264 (-1.141,0.612) 0.5548  2.196 (1.053,3.340) 0.0002
 rs1800629, TNF A G  13.4 2.1  GG/GA vs AA 0.274 (0.098,0.449) 0.0023  0.031 (-0.191,0.253) 0.7855
 rs3093662, TNF G A  6.4 8.5  AG vs other 0.38 (0.158,0.611) 0.0009  0.017 (-0.209,0.243) 0.8806
AMA1             
 rs739718, IL5 T C  31.6 21.0  CC vs TC/TT 0.163 (-0.163,0.489) 0.3266  -0.924 (-1.437,-0.411) 0.0004
MSP1             
 rs2304081, SLC22A4 G A  1.8 15.7  AG/AA vs GG 0.066 (-0.420,0.552) 0.7907  0.387 (0.165,0.610) 0.0007
 rs2070722, IRF1 G T  43.9 40.4  Additive T 0.001 (-0.134,0.135) 0.9930  0.226 (0.080,0.371) 0.0023
 rs739718, IL5 T C  31.6 21.0  CC vs TC/TT 0.162 (-0.194,0.518) 0.3713  -1.091 (-1.778,-0.404) 0.0019
 rs2239704, LTA G T  32.0 47.5  TT/GT vs GG 0.005 (-0.180,0.191) 0.9573  -0.371 (-0.591,-0.151) 0.0010
 rs1799964, TNF T C  14.4 19.0  CT vs CC/TT -0.075 (-0.288,0.137) 0.4864  0.355 (0.141,0.569) 0.0012
MSP2             
 rs5743809, TLR6 T C  6.0 4.8  CC vs TC/TT 1.562 (0.664,2.460) 0.0007  -0.570 (-2.167,1.027) 0.4842
 rs35415145, IL3 C T  1.7 3.0  CT vs other 0.020 (-0.411,0.451) 0.9267  -0.520 (-0.842,-0.197) 0.0016
 rs1799964, TNF T C  14.4 19.0  CT vs other -0.038 (-0.218,0.143) 0.6825  0.267 (0.102,0.432) 0.0015
 rs1012356, IL22 T A  48.1 41.5  AA/AT vs TT -0.294 (-0.467,-0.121) 0.0009  0.009 (-0.154,0.171) 0.9160
Total IgE             
 rs3148, IL3 G A  8.8 6.4  AA vs AG/GG -0.006 (-0.506,0.494) 0.9811  0.955 (0.428,1.483) 0.0004
 . rs20541, IL13 C T  27.6 7.6  TT vs CT/CC -0.251 (-0.399,-0.103) 0.0009  1.034 (0.292,1.777) 0.0063
 rs5498, ICAM1 A G  13.7 22.9  Additive G 0.013 (-0.073,0.100) 0.7657  0.109 (0.045,0.172) 0.0008
Effect sizes (slopes), 95% confidence intervals (CI) and p-values based on fitting linear regression models adjusting for age group and season
doi: 10.1371/journal.pone.0075675.t003
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